Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice

Journal of Clinical Pharmacology

Volumn 43, Issue 8, 2003, Pages 831-839

  Veronese, Maria L ^a   Gillen, Lisa P ^a   Burke, Joanne P ^a   Dorval, Ellen P ^a   Hauck, Walter W ^a   Pequignot, Ed ^a   Waldman, Scott A ^b   Greenberg, Howard E ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Bioavailability; Drug metabolism; Grapefruit juice; Inhibitors of CYP3A4; Intestinal and hepatic CYP3A4

Indexed keywords

CYTOCHROME P450 3A4; ERYTHROMYCIN DERIVATIVE; ERYTHROMYCIN N METHYL C 14; INTESTINE ENZYME; LIVER ENZYME; MIDAZOLAM; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME INHIBITION; ENZYME SUBSTRATE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; AREA UNDER CURVE; BEVERAGES; BIOLOGICAL AVAILABILITY; BREATH TESTS; CITRUS PARADISI; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; GASTROINTESTINAL AGENTS; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; INTESTINES; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM;

EID: 0038637264     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003256059     Document Type: Article

References (35)

1. Bailey DG, Spence JD, Munoz C, Arnold JMO: Interactions of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-269.
2. Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG: Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine - and its potential clinical relevance. Eur J Clin Pharmacol 1992;42:313-317.
3. Fuhr U, Harder S, Lopez-Rojas P, Muller-Peltzer H, Kern R, Staib AH: Increase of verapamil concentrations in steady state by coadministration of grapefruit juice. Arch Pharmacol 1994;349:R134.
4. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL: Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996;59:383-388.
5. Weber AR, Jager R, Borner A, et al: Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 1996;53:41-47.
6. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S: Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-28.
7. Kantola T, Kivisto KT, Neuvonen PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402.
8. Lilja JJ, Kivisto KT, Neuvonen PJ: Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-483.
9. Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ: Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993;36:457-459.
10. Ducharme MP, Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Br J Clin Pharmacol 1995;57:485-491.
11. Lown KS, Bailey DG, Fontana RJ, et al: Grapefruit juice increases felodipine oral availability in human by decreasing intestinal CYP3A4 protein expression. J Clin Invest 1997;99:2545-2553.
12. Shimada TH, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
13. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS: Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-1036.
14. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-1878.
15. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al: Differentiation of absorption and first pass gut and hepatic metabolism in humans: studies with cyclosporin. Clin Pharmacol Ther 1995;58:492-497.
16. Ameer B, Weintraub RA: Drug interactions with grapefruit juice. Clin Pharmacokinetics 1997;33(2):103-121.
17. Bailey DG, Arnold JMO, Bend JR, Tran LT, Spencer JD: Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharm 1995;40:135-140.
18. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-19.
19. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184.
20. Baker AL, Kotake AN, Schoeller DA: Clinical utility of breath tests for the assessment of hepatic function. Semin Liver Dis 1983;3:318-329.
21. Watkins PB: Breath tests as noninvasive assays of P450s. Methods Enzymol 1991;206:517-522.
22. Lown K, Kolars J, Turgeon DK, Merion R, Wrighton SA, Watkins PB: The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992;51:229-238.
23. 14C N-methyl] erythromycin breath test in healthy male volunteers. J Clin Pharmacol 1998;38:492-495.
24. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al: The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24.
25. Fabre G, Rahmani R, Placidi M, Combalbert J, Covo J, Cano JP, et al: Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol 1988; 37:4389-4397.
26. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
27. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al: First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
28. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556.
29. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ: The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998;54:53-58.
30. Wrighton SA, Ring BJ: Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmacol Res 1994; 11:921-924.
31. Backman JT, Olkkola KT, Neuvonen PJ: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
32. McCrea J, Prueksaritanont T, Gertz B, Carides A, Gillan L, Antonello S, et al: Erythromycin breath test (EBT) and oral midazolam (MDZ) concurrently as in vivo probes for CYP3A activity. Clin Pharmacol Ther 1998;63:154.
33. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications, 3rd ed. Baltimore: Williams & Wilkins, 1995;18-50.
34. Bailey DG, Bend JR, Arnold MO, Tran LT, Spence JD: Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996; 60:25-33.
35. Benet LZ, Schwartz JB: Appendix II: pharmacokinetic data, in: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1996;1712-1792.